BUZZ-TD Cowen initiates coverage on Brown & Brown with a "Buy" rating, shares rise accordingly
路透社2026/10/12 11:43October 12 - ** Insurance brokerage firm Brown & Brown (BRO.N) shares rose 1.45% to $63.79
** TD Cowen initiated coverage on the company with a “Buy” rating and a target price of $82, representing a 30% upside from the previous closing price
** The institution said the pressure from declining property insurance premiums has overshadowed its robust brokerage business
** Organic growth is expected to improve driven by synergies from the acquisition of Accession
** Of 24 brokers, 7 have a “Buy” or higher rating on the stock, 16 rate it “Hold,” and 1 rates it “Sell”; the median target price is $74.50 — data compiled by LSEG
** As of the previous trading day’s close, the stock is down 21.10% year to date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or fail to capture required context, Reuters does not guarantee the accuracy of the automated translation text, and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss caused by use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bristol-Myers Squibb (BMY.US) rises in pre-market trading! Two experimental drugs report positive results in Phase 3 clinical trials, diversifying and accelerating the pipeline
Bristol Myers Squibb's two experimental drugs, used to treat a rare endocrine cancer and a deadly lung disease, have achieved success in Phase III clinical trials, injecting momentum into the pharmaceutical company’s new product pipeline.
BUZZ-Enovix shares rise on preliminary revenue growth in the third quarter
Citius Pharma CEO Mazur presents at ThinkEquity Conference